Bempegaldesleukin Uses, Dosage, Side Effects and more
Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)).
Trade Name | Bempegaldesleukin |
Generic | Bempegaldesleukin |
Bempegaldesleukin Other Names | Bempegaldesleukin |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | January 7, 2025 at 1:49 am |